AzTrials
AzTrials

Cardiometabolic HealthSTARCHyNCT05994313

STARchy Staples: a Randomised Controlled Trial on Cardiometabolic Health

A study testing Habitual potato consumption and Habitual non-nutrient-dense staple consumption in people with Cardiometabolic Health, run by King's College London at 1 site in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

An investigation into habitual potato consumption (mashed, boiled, baked) on sleep quality and chronic glycaemic control, established risk factors for cardiometabolic diseases, versus habitual consumptions of non-nutrient-dense starchy staples (white rice, pasta, and couscous). Read more about this study

Who is it for?
Ages 40 to 80 yearsHealthy volunteers can take part
Conditions the study is for
Cardiometabolic Health
What is being tested?
Habitual potato consumption and Habitual non-nutrient-dense staple consumption
Could I receive a placebo?
No, everyone receives an active treatment
How many people
71 participants
Where
1 siteUnited Kingdom
Study dates
9 Sep 2023to 1 May 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 to 80 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Self-reported healthy adults
  • Aged 40-80 years old
  • Intake of ≤4 portions of fruits and vegetables (excluding potatoes) per day
  • Low sleep quality index of >5 (Pittsburgh sleep quality index).

Who cannot join

  • Shift workers and those with multiple jobs or carers who are required to wake through the night
  • Unwilling to refrain from dietary supplements
  • Unwilling to follow protocol and/or give informed consent
  • Diagnosed with Cardiovascular Disease (CVD), Type 2 Diabetes, Celiac disease, Insomnia, Sleep apnoea
  • Presence of gastrointestinal disorder
  • Users of drugs that are likely to alter gastrointestinal motility or nutrient absorption
Show all 21Show fewer
  • History of substance abuse or alcoholism
  • Currently pregnant, planning pregnancy, breastfeeding, or having had a baby 12 months prior
  • Weight change of >3kg in the preceding 2 months
  • BMI <18.5kg/m2 or > 35kg/m2,
  • Current smokers, or individuals who quit smoking in the last 6-months
  • Frequently consume wholemeal products (1-2 times per day, in the short screening FFQ)
  • Never consumed refined starchy staples, such as white pasta or rice (rarely or never, in the short screening FFQ)
  • High potato consumption (4-6 times per week, in the short screening FFQ)
  • High risk of obstructive sleep apnoea (answer yes to >3 questions, in STOP-Bang questionnaire)
  • Vegetarian, Vegan, or pescatarian dietary preferences.
  • Diagnosed with mental health disorders, and/or on medicine for their mental health (antipsychotics, antidepressants, beta-blockers)
  • Chronic user of antihistamines
  • Fasting glucose >7mmol/l (finger prick test at baseline clinic)
  • Is taking weight loss, or glucose regulating medications.
  • Has been unstable on blood pressure lowering medications for at least 3-months prior to enrollment.

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site
  • Department of Nutritional Sciences, Franklin Wilkins Building, Waterloo campus.

    Lambeth, London, SE1 9NH

Other trials in United Kingdom

About this study

An investigation into habitual potato consumption (mashed, boiled, baked) on sleep quality and chronic glycaemic control, established risk factors for cardiometabolic diseases, versus habitual consumptions of non-nutrient-dense starchy staples (white rice, pasta, and couscous).

Read the detailed description

In the last few years, researchers have undergone efforts to conduct well-controlled trials to investigate the cardiometabolic health effect of consuming potatoes as part of a healthy diet. None to our knowledge, however, have investigated the harmful dyad of poor sleep and adverse glycaemic control, 2 interrelated factors which can exacerbate cardiometabolic (CM) health outcomes. The nutrient density of potatoes, namely being the single richest source of potassium per serving, provides a plausible mechanism in which the potatoes may act to improve health markers.

The primary objective of this study is to investigate whether consuming a portion of nutrient-dense potatoes in the evening meal, in place of other refined carbohydrates, can improve sleep quality, and improve nocturnal, and 24-hour, glycaemic control, both risk factors for CM diseases. Secondly, this study aims to investigate the effects of potato consumption on endothelium-dependent vasodilation, which can further interrelate to this web of interactions, and other measures of CM health.

Study design: A randomised, two-parallel arm, in-clinic and remote, 12-week dietary intervention study.

Study population: Healthy male and female 40-80-year-olds, who consume ≤4 fruits and vegetables per day and have sub-optimal sleep quality.

The study aims to recruit a total of 80 participants, allowing for an estimated 15% dropout rate, to reach 80% power at a significance level of 0.025 (based on two outcomes). The allocation ratio is 1:1 intervention to control.

Statistical analysis: Differences between groups (minimized for age, gender, BMI) will be analysed using Linear mixed models for outcomes with 3 timepoints (urinary outcomes, dietary intake data), with change being the dependent factor, subject ID as a random effect, treatment and season as fixed effects, and baseline outcome and BMI as covariates. Variables with 2 timepoints will be assessed with an ANCOVA regression model.

Locations:

Metabolic Research Unit, 4th floor, Franklin Wilkins Building, Waterloo campus, Kings College London, SE1 9NH.

Screening assessment: Participants will be initially assessed for suitability against the inclusion-exclusion criteria via an online questionnaire. The outputs of the questionnaire will be assessed by the study team. Some exclusion criteria will be assessed at the baseline clinic visit before any baseline measures are provided.

Study duration: There will be a 2-week run-in period, followed by a 12-week dietary intervention.

Dietary intervention: The intervention (potato group) will consume at least 230 g of white potatoes (including fresh and frozen baked, boiled, and mashed potato products) in their evening meal, providing ~1000 mg potassium, enough to increase national median intakes up to recommended intakes. The control group will consume isoenergetic amounts of non-nutrient-dense starchy staples (white pasta, white rice, or couscous).

Although participants cannot be blinded to what they're consuming, they will be blinded to whether they are in the control or the intervention group, to reduce the risk of bias.

Participants will be required to source the potatoes and make these meals themselves, however, they will be provided with rotating 4-weekly recipe cards, with instructions on how to prepare meals.

Participants will be required to attend several virtual one-to-ones with the study team, including an introductory call, a virtual run-in induction where they will be run through the study equipment, and 2 in-person clinic visits. Participants will be responsible for applying some study equipment from home, to reduce clinic visits and improve study retention.

Compliance: Compliance will be monitored via several methods. Firstly, 24 h urinary potassium excretion, which is shown to recover 75% of potassium intake, secondly self-reported compliance will be measured through evening meal checklists. We also plan to use dietary recalls at weeks 2, 4, and 8 to reinforce dietary advice, and to make adaptations to rotating menus based on individual needs, if participants are struggling with adherence. Detailed dietary intake will be assessed through 4-day food diaries at weeks 0, 6, and 12- this data will be used for analysis.

Flow-mediated dilation: A Doppler ultrasound will be utilised to capture continuous ultrasound videos to measure flow-mediated dilation. These will be analysed with automated software provided by Maastricht University.

Anthropometry: Weight, height, waist and hip circumference, blood pressure, and body fat will be taken using standard procedures, in duplicates by a trained researcher at baseline and endline clinic visits.

Blood samples: Fasting blood samples will be collected from a superficial antecubital vein via venepuncture before and after the dietary intervention, by a trained researcher.

Participants will be asked to record and monitor the following information:

Self-reported compliance with dietary intervention, weekly weight (data diaries), and habitual dietary intake (4-day diet diaries).

Being tested
Habitual potato consumption, Habitual non-nutrient-dense staple consumption
Keywords
Sleep efficiency, Glycemic control, Flow mediated dilation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Habitual potato consumptionDietary supplement

    Potatoes are to be consumed in the evening meal, every evening for 12-weeks.

  • Habitual non-nutrient-dense staple consumptionDietary supplement

    White rice, white pasta or white couscous are to be consumed in the evening meal, every evening for 12-weeks.

Study groups in NCT05994313
Study groupRoleWhat they receive
Habitual potato consumptionExperimentalAt least 230g of white potatoes, including fresh and frozen, baked, boiled, and mashed potatoes, will be consumed in the evening meal, in replacement of non-nutrient-dense starchy staples, for 12 weeks.
Receives: Dietary Supplement: Habitual potato consumption
Habitual non-nutrient-dense staple consumptionActive comparatorIsocaloric amounts of non-nutrient-dense starchy staples, such as white rice, white pasta, and white couscous, will be consumed in the evening meal for 12 weeks.
Receives: Dietary Supplement: Habitual non-nutrient-dense staple consumption

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in 7-day sleep efficiency

    Differences in % sleep efficiency at endline vs baseline. Sleep efficiency % is described as the total time spent asleep/ total time spent in bed x 100.

    Measured: Pre- and post-intervention: 12 weeks

  2. Change in 12-day nocturnal mean glucose

    Differences in mean nocturnal glucose, measured using a Freestyle Libre 3 continuous glucose monitor.

    Measured: Pre- and post-intervention: 12 weeks

Secondary outcomes (33)
  1. Change in mean nocturnal AUC

    Difference in 12-day mean nocturnal Area Under the Curve (AUC).

    Measured: Pre- and post-intervention: 12 weeks

  2. Difference in nocturnal TIR

    Difference in 12-day nocturnal Time In Range for non-diabetic populations (TIR nd).

    Measured: Pre- and post-intervention: 12 weeks

  3. Change in the nocturnal CV%

    Difference in 12-day nocturnal coefficient of variation (CV%)

    Measured: Pre- and post-intervention: 12 weeks

  4. Change in nocturnal MAGE

    Difference in 12-day nocturnal Mean Amplitude of Glycemic Excursions (MAGE).

    Measured: Pre- and post-intervention: 12 weeks

  5. Change in nocturnal MODD

    Difference in 12-day nocturnal Mean of Daily Differences (MODD).

    Measured: Pre- and post-intervention: 12 weeks

  6. Change in mean daytime glycaemic control

    Differences in 12-day mean daytime glucose.

    Measured: Pre- and post-intervention: 12 weeks

  7. Difference in daytime TIR

    Difference in 12-day daytime Time In Range for non-diabetic populations (TIR nd).

    Measured: Pre- and post-intervention: 12 weeks

  8. Change in the daytime CV%

    Difference in 12-day daytime coefficient of variation (CV%)

    Measured: Pre- and post-intervention: 12 weeks

  9. Change in daytime MAGE

    Difference in 12-day daytime Mean Amplitude of Glycemic Excursions (MAGE).

    Measured: Pre- and post-intervention: 12 weeks

  10. Change in daytime MODD

    Difference in 12-day daytime Mean of Daily Differences (MODD).

    Measured: Pre- and post-intervention: 12 weeks

  11. Change in mean 24-hour glycaemic control

    Differences in 12-day mean 24-hour glucose.

    Measured: Pre- and post-intervention: 12 weeks

  12. Difference in 24-hour TIR

    Difference in 12-day 24-hour Time In Range for non-diabetic populations (TIR nd).

    Measured: Pre- and post-intervention: 12 weeks

  13. Change in the 24-hour CV%

    Difference in 12-day 24-hour coefficient of variation (CV%)

    Measured: Pre- and post-intervention: 12 weeks

  14. Change in 24-hour MAGE

    Difference in 12-day 24-hour Mean Amplitude of Glycemic Excursions (MAGE).

    Measured: Pre- and post-intervention: 12 weeks

  15. Change in 24-hour MODD

    Difference in 12-day 24-hour Mean of Daily Differences (MODD).

    Measured: Pre- and post-intervention: 12 weeks

  16. Change in heart rate variability during mental stress

    A combination of time domain, frequency domain and non-linear methods (NN intervals, heart rate, rMSSD, pNN50, SDNN, TINN, SDANN, SD1/SD2, High Frequency, Low Frequency, Very Low Frequency, Ultra Low Frequency HF:LF, total power), will be compared from pre- to post-mental stress.

    Measured: Pre- and post-intervention: 12 weeks

  17. Change in 24-hour heart rate variability

    A combination of time domain, frequency domain and non-linear methods (NN intervals, heart rate, rMSSD, pNN50, SDNN, TINN, SDANN, SD1/SD2, High Frequency, Low Frequency, Very Low Frequency, Ultra Low Frequency HF:LF, total power).

    Measured: Pre- and post-intervention: 12 weeks

  18. Change in Endothelial function

    Mean differences in flow-mediated dilation (%)

    Measured: Pre- and post-intervention: 12 weeks

  19. Nocturnal continuous blood pressure

    Measured with an Aktiia Photoplethysmography watch.

    Measured: Whole 12 week period.

  20. Daytime continuous blood pressure

    Measured with an Aktiia Photoplethysmography watch.

    Measured: Whole 12 week period.

  21. Change in blood pressure

    Diastolic and systolic blood pressure, measured by oscillometry.

    Measured: Pre- and post-intervention: 12 weeks

  22. Change in plasma lipids

    Including: total lipids, HDL and LDL-cholesterol, and Triacylglycerols.

    Measured: Pre- and post-intervention: 12 weeks

  23. Change in fasting plasma glucose

    Fasting plasma glucose concentration

    Measured: Pre- and post-intervention: 12 weeks

  24. Change in fasting insulin

    Fasting insulin concentration

    Measured: Pre- and post-intervention: 12 weeks

  25. Change in fasting HbA1C

    Fasting HbA1C concentration

    Measured: Pre- and post-intervention: 12 weeks

  26. Change in serum potassium

    Serum potassium mmol/L

    Measured: Pre- and post-intervention: 12 weeks

  27. Change in sleep duration, in minutes

    Sleep duration (minutes)

    Measured: Pre- and post-intervention: 12 weeks

  28. Change in sleep duration, in %

    Sleep duration (%)

    Measured: Pre- and post-intervention: 12 weeks

  29. Change in sleep latency

    Sleep latency is defined as the time it takes to fall asleep from the time intended to fall asleep.

    Measured: Pre- and post-intervention: 12 weeks

  30. Change in body fat %

    Body fat % measured using TANITA bioelectrical impedance scales

    Measured: Pre- and post-intervention: 12 weeks

  31. Change in waist circumference (cm)

    Waist circumference (cm)

    Measured: Pre- and post-intervention: 12 weeks

  32. Change in BMI kg/m2

    BMI kg/m2, measured using a stadiometer and TANITA scales

    Measured: Pre- and post-intervention: 12 weeks

  33. Calystegine potato biomarker

    Calystegine will be analysed as an exploratory biomarker of potato consumption (a polyhydroxylated nortropane alkaloid), by Triple Quadrupole mass spectrometry (MS/MS).

    Measured: Pre- and post-intervention: 12 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Aug 2023
  2. Study start9 Sep 2023
  3. Primary completion1 May 2025
  4. Study completion1 May 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Parallel groups
Model description
12-week Randomised controlled trial
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
71 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05994313
Sponsor's protocol ID
RCT-DNS-SS-2023
Acronym
STARCHy
Status last verified
Aug 2025
First submitted
1 Aug 2023
Last updated
16 Sep 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: The study protocol, Statistical Analysis Plan, and Informed Consent have been uploaded on 01/09/2025, before statistical analysis commenced. De-identified data will be shared upon reasonable request and in collaboration with the study investigators, beginning 12 months after publication of the main trial results.

Publications

  • Robertson TM, Alzaabi AZ, Robertson MD, Fielding BA. Starchy Carbohydrates in a Healthy Diet: The Role of the Humble Potato. Nutrients. 2018 Nov 14;10(11):1764. doi: 10.3390/nu10111764.

    PubMed 30441846
  • McGill CR, Kurilich AC, Davignon J. The role of potatoes and potato components in cardiometabolic health: a review. Ann Med. 2013 Nov;45(7):467-73. doi: 10.3109/07853890.2013.813633. Epub 2013 Jul 15.

    PubMed 23855880
  • Stone MS, Martin BR, Weaver CM. Short-Term RCT of Increased Dietary Potassium from Potato or Potassium Gluconate: Effect on Blood Pressure, Microcirculation, and Potassium and Sodium Retention in Pre-Hypertensive-to-Hypertensive Adults. Nutrients. 2021 May 11;13(5):1610. doi: 10.3390/nu13051610.

    PubMed 34064968
  • Johnston EA, Petersen KS, Kris-Etherton PM. Daily intake of non-fried potato does not affect markers of glycaemia and is associated with better diet quality compared with refined grains: a randomised, crossover study in healthy adults. Br J Nutr. 2020 May 14;123(9):1032-1042. doi: 10.1017/S0007114520000252. Epub 2020 Jan 22.

    PubMed 31964428
  • Macdonald-Clarke CJ, Martin BR, McCabe LD, McCabe GP, Lachcik PJ, Wastney M, Weaver CM. Bioavailability of potassium from potatoes and potassium gluconate: a randomized dose response trial. Am J Clin Nutr. 2016 Aug;104(2):346-53. doi: 10.3945/ajcn.115.127225. Epub 2016 Jul 13.

    PubMed 27413123
  • D'Elia L, Masulli M, Cappuccio FP, Zarrella AF, Strazzullo P, Galletti F. Dietary Potassium Intake and Risk of Diabetes: A Systematic Review and Meta-Analysis of Prospective Studies. Nutrients. 2022 Nov 12;14(22):4785. doi: 10.3390/nu14224785.

    PubMed 36432472

Questions about this trial

What is this clinical trial studying?

A study testing Habitual potato consumption and Habitual non-nutrient-dense staple consumption in people with Cardiometabolic Health, run by King's College London at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 16 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in 7-day sleep efficiency (time frame: Pre- and post-intervention: 12 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05994313, which also lists 6 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Sep 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in